Toragen focuses on repurposing antiviral medications and creating innovative immunotherapies for the treatment of viral-related cancers. Our team consists of experts from the industry with extensive experience in early-phase biotech startups, translational drug research, and groundbreaking Phase III clinical trials. Toragen is preparing to launch a Phase I clinical study with its primary compound for HPV-related malignancies and is actively seeking investment for further research and development.